BioInvent strengthens management team with appointment of Jonas Källmén as Chief Financial Officer
BioInvent strengthens management team with appointment of Jonas Källmén as Chief Financial Officer Lund, Sweden: BioInvent International AB (SAX: BINV) is strengthening its management team with the appointment of Jonas Källmén as Chief Financial Officer. Jonas (36) will take up his position on 29 October, joining the Company from Precise Biometrics AB, another Lund-based company listed on the Stockholm Stock Exchange's O-list. Prior to Precise, Jonas worked with cash management and finance issues in a major international company - Tetra Laval group - for 8 years. "Strengthening the financial department of BioInvent is a natural consequence of our flotation earlier this year. Jonas comes from an enterprise that has undergone the same process and he will therefore be able to contribute valuable experience - I look forward to working with him as we move the Group forward," said Svein Mathisen, President and CEO of BioInvent International AB. For further information, please contact: BioInvent International AB Buchanan Communications Svein Mathisen Nicola How President and CEO Tel: +44 20 7466 5000 Tel: +46 46 286 85 67 Mobile: +46-708-97 82 13 E-mail: sm@bioinvent.com Notes to Editors: BioInvent International AB, recently floated on the O-list of the Swedish Exchange, is a biotechnology company devoted to providing state- of-the-art antibody technology to the pharmaceutical and biotech industry. A cornerstone is its proprietary human antibody gene library, n-CoDeR(TM). This is a collection of more than ten billion functional antibody genes that are ready to be screened against desired antigens. n- CoDeR(TM) has been used successfully for the isolation of antibody fragments with specificity for a number of antigens, including peptides, proteins and carbohydrates. BioInvent offers biotechnology and pharmaceutical companies access to n-CoDeR(TM) through collaborative research and development programs. BioInvent's capabilities in large-scale contract manufacturing of protein-based drugs through a state-of-the-art cGMP-certified facility further underpin its competitiveness in the antibody arena. BioInvent has been supplying monoclonal antibodies, fusion proteins and other recombinant proteins to the world's leading pharmaceutical and biotechnology companies for therapeutic use since 1988. These antibodies and proteins are used in all phases of clinical trials in both the US and across Europe. The cGMP-certified manufacturing facility is designed to meet FDA and EU regulations from early clinical development to commercial scale-up, with multi-kilogram annual capacity. BioInvent is headquartered in Lund, Sweden, employing a total of 100 people. For additional information, see www.bioinvent.com. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00880/wkr0001.doc http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00880/wkr0002.pdf